· 4basebio and Circio are combining CircioŽs circVec circular RNA expression
system with 4basebioŽs proprietary synthetic DNA formats hpDNAT and opDNAT
  · 4basebioŽs unique nanoparticle delivery platform, HermesT, allows for
improved delivery of synthetic DNA vectors over conventional LNPs
  · CircioŽs circVec technology has shown enhanced expression level and
durability vs. standard mRNA approach, and together the technologies are
expected to create a powerful therapeutic combination

Oslo, Norway 21 January 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, today announces that it has entered a partnership with 4basebio
PLC of Cambridge, UK, for joint development and in vivo delivery testing of
synthetic circVec DNA vectors.

"The circVec technology achieves up to 70 times prolonged RNA half-life and 15
-fold increase in protein levels vs. standard mRNA-based expression in vivo
using plasmid DNA," said Dr. Thomas Hansen, CTO of Circio. "We have therefore
now partnered with 4basebio, a world-leader in next-generation DNA vectors for
therapeutic applications. Combining 4basebioŽs vector and delivery expertise
with CircioŽs circVec powerful expression technology has the potential to create
a durable, repeat-dosable, non-viral platform for future synthetic DNA gene
therapies."

Dr. Emily Young, Head of Non-Viral Delivery for 4Basebio added: "We are
delighted to partner with Circio to develop the next generation of DNA gene
therapies and vaccines. 4Basebio's synthetic DNA offers fast, scalable and cost
-effective manufacturing advantages compared to plasmid DNA. Combining these
capabilities with the superior expression of Circio's circVec technology, in
addition to 4Basebio's Hermes DNA-delivery platform, promises to establish
extremely robust and durable DNA therapeutics."

Under the collaboration, 4basebio has successfully developed and validated
circVec vectors in their proprietary synthetic hpDNAT and opDNAT formats,
including formulation into Hermes LNP formulations optimized for in vivo
delivery of DNA payloads. Both parties will now in parallel proceed to test the
performance of these circVec-op/hpDNA vectors in mouse models. If successful,
the results will create the foundation for a continued collaboration to develop
and test future therapeutic candidates for genetic medicine, vaccines and other
potential applications.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter - Hunter PR
Phone:+44 7821 255568 (http://tel:+447821255568)
Email: neiljameshunter@gmail.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.